Physician profile
Jeff Pinto
NPI 1043843915
$1,153.35
in general payments reported to CMS, 2019-2025
15 companies · $28.87 in 2025
The $28.87 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $487 · 2022: $476 · 2023: $142 · 2024: $19.51 · 2025: $28.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $176 · Education: $14.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $176.01 |
| Education | $14.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $253.01 | 2021-2023 | |
| Amgen INC. | $164.26 | 2021-2023 | Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $160.03 | 2021-2023 | |
| Glaxosmithkline, LLC. | $115.59 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $110.27 | 2021-2022 | |
| Fresenius USA Marketing, INC. | $73.25 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $60.36 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $42.83 | 2021 | |
| Opko Pharmaceuticals, LLC | $33.43 | 2021-2023 | Rayaldee |
| Calliditas Therapeutics US INC. | $28.87 | 2025 | Tarpeyo |
| Horizon Therapeutics Plc | $28.13 | 2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $28.08 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $24.04 | 2021 | |
| Novo Nordisk INC | $19.51 | 2024 | Rivfloza |
| Vifor Pharma, INC. | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeff Pinto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.